Viewpoint Capital Management LLC Increases Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Viewpoint Capital Management LLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 18.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,416 shares of the biotechnology company’s stock after buying an additional 2,416 shares during the period. Viewpoint Capital Management LLC’s holdings in ADMA Biologics were worth $102,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of ADMA Biologics by 182.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company’s stock valued at $5,761,000 after purchasing an additional 1,039,893 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of ADMA Biologics by 111.1% during the 3rd quarter. HighTower Advisors LLC now owns 72,517 shares of the biotechnology company’s stock valued at $258,000 after acquiring an additional 38,160 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in shares of ADMA Biologics in the 3rd quarter worth approximately $58,000. Invesco Ltd. increased its stake in ADMA Biologics by 8.5% in the 3rd quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company’s stock valued at $19,393,000 after purchasing an additional 426,446 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in ADMA Biologics by 16.9% during the third quarter. Federated Hermes Inc. now owns 773,245 shares of the biotechnology company’s stock worth $2,768,000 after purchasing an additional 111,631 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Raymond James lifted their price target on ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. Cantor Fitzgerald increased their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, HC Wainwright increased their target price on ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $11.00.

ADMA Biologics Price Performance

ADMA stock traded up $0.23 during midday trading on Friday, hitting $11.18. The stock had a trading volume of 10,330,153 shares, compared to its average volume of 2,870,412. The company’s 50-day moving average price is $9.11 and its 200 day moving average price is $6.68. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. ADMA Biologics, Inc. has a 12-month low of $3.06 and a 12-month high of $11.27.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm had revenue of $81.90 million during the quarter, compared to analyst estimates of $77.28 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. The business’s quarterly revenue was up 43.9% compared to the same quarter last year. Analysts anticipate that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the transaction, the chief executive officer now owns 2,081,475 shares of the company’s stock, valued at $22,313,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.